Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Thames Water agrees payment plan for Ofwat penalty bill

(Sharecast News) - Thames Water has secured a payment plan with Ofwat for £122.7m in penalties, it was confirmed on Wednesday, as it raced to avoid collapse and potential temporary nationalisation. The UK's largest water company, serving 16 million customers, would pay £24.5m - 20% of the total fines - by 30 September, with the remaining balance due on the earliest of three dates - 30 days after a financial restructuring, 30 days after exiting a special administration regime (SAR) if one is imposed, or by a backstop deadline of 31 March 2030.

Thames confirmed the fines "will not be funded by customer bills", without further explaining how they would be funded.

The penalties were imposed in May after Ofwat found "significant" failings in Thames's wastewater operations, leading to sewage pollution, and over dividend payments made despite poor environmental and service performance.

The £104.5m wastewater fine was the largest in the regulator's history, while the £18.2m dividend penalty was the first of its kind in the sector.

"This payment plan continues to hold Thames Water to account for their failures but also recognises the ongoing equity raise and recapitalisation process," said Ofwat's senior director of enforcement, Lynn Parker.

"Our focus remains on ensuring that the company takes the right steps to deliver a turnaround in its operational performance and strengthen its financial resilience to the benefit of customers."

The deal came as Thames's creditors negotiated a rescue package that could inject £5bn of new capital while writing off around £12bn of debt.

The government has appointed insolvency specialists FTI Consulting to prepare for a potential SAR should those talks fail.

Thames said it "continues to work closely with stakeholders to secure a market-led recapitalisation which delivers for customers and the environment as soon as practicable".

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.